Sorafenib Tosylate contains not less than 97.5% and not more than 102.0% of Sorafenib Tosylate (C21H16ClF3N4O3‧C7H8SO3), calculated on anhydrous basis.

共有 1 個藥物證書使用此成份

煞拉速肌瘤靶泊甲苯磺酸鹽
Sorafenib Tosylate

• 申請商: 西海生技股份有限公司
• 適應症: 抗腫瘤藥
• 發證日期: 2023-05-23